Concepedia

Suparna Wedam

SW

Statistics

Publications

15

Citations

1.8K

H-Index

14

Active since

2004

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Cancer Research

National Institutes of Health

National Cancer Institute

Suparna Wedam is an author at United States Food and Drug Administration specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2004–2021

15

Publications

15

Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

Suparna Wedam, Jennifer A. Low, Sherry X. Yang et al. · Journal of Clinical Oncology · 2006 · 524 citations · Full text

, , +14

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 297 citations

, , +17

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer

Jennifer A. Low, Suparna Wedam, James J. Lee et al. · Journal of Clinical Oncology · 2005 · 215 citations

, , +15

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

Suparna Wedam, Lola A. Fashoyin‐Aje, Erik Bloomquist et al. · Clinical Cancer Research · 2019 · 156 citations

, , +15

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Amanda J. Walker, Suparna Wedam, Laleh Amiri‐Kordestani et al. · Clinical Cancer Research · 2016 · 137 citations

, , +17

1–5 of 15